Literature DB >> 18446064

An NH2-terminal truncated cytochrome P450 CYP3A4 showing catalytic activity is present in the cytoplasm of human liver cells.

Songhee Jeon1, Keon Hee Kim, Chul Ho Yun, Boo-Whan Hong, Yoon-Seok Chang, Ho-Seong Han, Yoo-Seok Yoon, Won-Bum Choi, Soyun Kim, Ai-Young Lee.   

Abstract

Cytochrome P450 3A4 (CYP3A4), is the dominant human liver hemoprotein enzyme localized in the endoplasmic reticulum (ER), and is responsible for the metabolism of more than 50% of clinically relevant drugs. While we were studying CYP3A4 expression and activity in human liver, we found that anti-CYP3A4 antibody cross-reacted with a lower band in liver cytoplasmic fraction. We assessed the activities of CYP3A4 and its truncated form in the microsomal and cytoplasmic fraction, respectively. In the cytoplasmic fraction, truncated CYP3A4 showed catalytic activity when reconstituted with NADPH-cytochrome P-450 reductase and cytochrome b5. In order to determine which site was deleted in the truncated form in vitro, we transfected cells with N-terminal tagged or C-terminal tagged human CYP3A4 cDNA. The truncated CYP3A4 is the N-terminal deleted form and was present in the soluble cytoplasmic fraction. Our result shows, for the first time, that N-terminal truncated, catalytically active CYP3A4 is present principally in the cytoplasm of human liver cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18446064      PMCID: PMC2679303          DOI: 10.3858/emm.2008.40.2.254

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  30 in total

Review 1.  Interactions between cytochrome P450 and cytochrome b5.

Authors:  J B Schenkman; I Jansson
Journal:  Drug Metab Rev       Date:  1999-05       Impact factor: 4.518

2.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

3.  The CYP3A4*18 allele, the most frequent coding variant in asian populations, does not significantly affect the midazolam disposition in heterozygous individuals.

Authors:  Su-Jun Lee; Sang Seop Lee; Hye-Eun Jeong; Ji-Hong Shon; Ji-Young Ryu; Yu Eun Sunwoo; Kwang-Hyeon Liu; Wonku Kang; Young-Ju Park; Chi-Mann Shin; Jae-Gook Shin
Journal:  Drug Metab Dispos       Date:  2007-08-27       Impact factor: 3.922

4.  Effect of the adrenal 11-beta-hydroxylase inhibitor metyrapone on human hepatic cytochrome P-450 expression: induction of cytochrome P-450 3A4.

Authors:  J L Harvey; A J Paine; P Maurel; M C Wright
Journal:  Drug Metab Dispos       Date:  2000-01       Impact factor: 3.922

5.  A soluble NH(2)-terminally truncated catalytically active form of rat cytochrome P450 2E1 targeted to liver mitochondria(1).

Authors:  E P Neve; M Ingelman-Sundberg
Journal:  FEBS Lett       Date:  1999-10-29       Impact factor: 4.124

6.  Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Junko Mochizuki; Shigeto Murakami; Akira Sanjo; Ichiro Takagi; Setsuko Akizuki; Akihiro Ohnishi
Journal:  J Gastroenterol Hepatol       Date:  2005-08       Impact factor: 4.029

Review 7.  Cytochrome P-450 3A4: regulation and role in drug metabolism.

Authors:  F P Guengerich
Journal:  Annu Rev Pharmacol Toxicol       Date:  1999       Impact factor: 13.820

8.  Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method.

Authors:  V Ozdemir; W Kalow; B K Tang; A D Paterson; S E Walker; L Endrenyi; A D Kashuba
Journal:  Pharmacogenetics       Date:  2000-07

9.  Identification and characterization of genes associated with human hepatocellular carcinogenesis.

Authors:  N Kondoh; T Wakatsuki; A Ryo; A Hada; T Aihara; S Horiuchi; N Goseki; O Matsubara; K Takenaka; M Shichita; K Tanaka; M Shuda; M Yamamoto
Journal:  Cancer Res       Date:  1999-10-01       Impact factor: 12.701

10.  Cytochrome P450 1A1 (CYP1A1) polymorphisms and breast cancer risk in Korean women.

Authors:  Aesun Shin; Daehee Kang; Ji-Yeob Choi; Kyoung-Mu Lee; Sue Kyung Park; Dong-Young Noh; Sei-Hyun Ahn; Keun-Young Yoo
Journal:  Exp Mol Med       Date:  2007-06-30       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.